Increase in thyroid cancer in US attributed to improved early detection

May 09, 2006

Although the incidence of thyroid cancer has more than doubled in the past 30 years, the rise is being attributed to improved diagnostic techniques of previously undetected disease, rather than a true increase in the occurrence of thyroid cancer, according to a study in the May 10 issue of JAMA.

While the incidence of many head and neck cancers in the United States is decreasing, a number of registries have reported that the incidence of thyroid cancer is increasing. Some investigators have attributed the increase to environmental radiation, while others believe it could be from increased diagnostic scrutiny, according to background information in the article.

Although some thyroid cancers can spread and cause death, thyroid cancer has also been recognized to exist in a subclinical (before symptoms) form. Autopsy studies have revealed that many individuals not known to have thyroid cancer during their lifetime had thyroid cancer, particularly papillary cancers. As diagnostic techniques for thyroid cancer have become more sensitive, such as with the advent of ultrasound and fine-needle aspiration, it has become possible to detect this subclinical disease. Thus, while increasing incidence of thyroid cancer might reflect an increase in the true occurrence of disease, it might also reflect increased diagnostic scrutiny or changes in diagnostic criteria. Examination of the reasons underlying an increase in the incidence of thyroid cancer is important, because if there is an increase in the true occurrence of disease, efforts should be made to address its cause and aid those at greatest risk of developing the disease.

Louise Davies, M.D., M.S., and H. Gilbert Welch, M.D., M.P.H., of the Department of Veterans Affairs Medical Center, White River Junction, Vt., examined the trends in thyroid cancer incidence, histology, size distribution, and death in the U.S. to determine whether the patterns suggest a true change in thyroid cancer incidence or an apparent change based on increased diagnostic scrutiny. The researchers analyzed data, from 1973-2002, from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and data on deaths attributed to thyroid cancer from the National Vital Statistics System.

The researchers found that the incidence of thyroid cancer rose from 3.6 per 100,000 in 1973 to 8.7 per 100,000 in 2002--a 2.4-fold increase. This 5.1 per 100,000 growth in the incidence of thyroid cancer was virtually entirely due to an increase in papillary thyroid cancer, which rose by 5 per 100,000, a 2.9-fold increase. Most of this increase is the result of increased detection of small cancers. Forty-nine percent of the increase consisted of cancers measuring 1 centimeter (cm) or less; 87 percent consisted of cancers measuring 2 cm or less. There was no significant change in the incidence of other types of thyroid cancer. Despite increasing incidence, the death rate from thyroid cancer has remained stable.

"Given the known prevalence of small, asymptomatic papillary thyroid cancers at autopsy, we believe this suggests that increased diagnostic scrutiny has caused an apparent increase in incidence of cancer rather than a real increase," the researchers write. "Because many of these cancers would likely never have caused symptoms during life, epidemiologists have labeled the phenomenon 'overdiagnosis'--a term perhaps most familiar in the setting of prostate cancer," the authors write.

"Further studies will be needed to determine if a more cautious diagnostic approach--perhaps simply providing follow-up for symptomatic thyroid nodules-- is worthwhile. In addition, papillary cancers smaller than 1 cm could be classified as a normal finding," the researchers conclude.
(JAMA. 2006;295:2164-2167. Available pre-embargo to the media at

Editor's Note: This study was supported in part by a Research Enhancement Award from the Department of Veterans Affairs and by the University of Washington Robert Wood Johnson Clinical Scholars Program-VA Scholars, Seattle.

Editorial: Managing Small Thyroid Cancers

In an accompanying editorial, Ernest L. Mazzaferri, M.D., of the University of Florida, Gainesville, comments of the findings of Davies et al.

"The American Thyroid Association evidence-based management guidelines for patients with thyroid nodules and differentiated thyroid cancer have recommendations relevant to this debate [of appropriate diagnosis]. First, thyroid sonography should be performed in all patients with 1 or more suspected thyroid nodules; second, fine-needle aspiration biopsy (FNAB) is the procedure of choice for evaluating thyroid nodules; and third, when several nodules larger than 1 to 1.5 cm are present, those with a suspicious sonographic appearance should be biopsied preferentially. Patients with nodules that are 8 to 9 mm in size and that have suspicious ultrasonographic findings, suspicious cervical lymph nodes, or a history of radiation exposure or familial thyroid cancer should be considered for ultrasound-guided FNAB. Smaller nodules most likely can be followed up over several years without FNAB if they are not increasing in size."

(JAMA. 2006;295:2179-2182. Available pre-embargo to the media at

The JAMA Network Journals

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to